Efficacy of IsaPomDex triplet therapy in double refractory multiple myeloma patients in real clinical practice in Russia
Background. Data from real-life clinical practice studies provide additional information on the efficacy of new antitumor therapy regimens, including in patients who meet exclusion criteria for clinical trials.Aim. To evaluate the Isaomex triplet efficacy in multiple myeloma patients in real clinica...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2024-12-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/979 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850024461312458752 |
|---|---|
| author | M. V. Solovev M. V. Solovevа L. P. Mendeleeva T. I. Pospelova N. V. Skvortsova S. V. Voloshin A. D. Garifullin A. S. Chuprakova T. A. Mitina I. S. Usankin I. V. Vasileva N. V. Medvedeva V. V. Ryabchikova M. Ya. Kiseleva G. A. Dudina Yu. S. Gammershmidt O. S. Kuznetsova Yu. V. Dolgushina G. B. Kuchma T. N. Tsyganok E. N. Misyurina E. I. Zhelnova A. V. Kopylova M. N. Zakharova A. V. Korobkin G. S. Tumyan A. A. Semenova E. G. Kirillova E. M. Volodicheva V. I. Bakhtina T. I. Olkhovik N. R. Solovkova M. V. Demchenkova O. E. Ochirova O. L. Panteleeva V. S. Abramova |
| author_facet | M. V. Solovev M. V. Solovevа L. P. Mendeleeva T. I. Pospelova N. V. Skvortsova S. V. Voloshin A. D. Garifullin A. S. Chuprakova T. A. Mitina I. S. Usankin I. V. Vasileva N. V. Medvedeva V. V. Ryabchikova M. Ya. Kiseleva G. A. Dudina Yu. S. Gammershmidt O. S. Kuznetsova Yu. V. Dolgushina G. B. Kuchma T. N. Tsyganok E. N. Misyurina E. I. Zhelnova A. V. Kopylova M. N. Zakharova A. V. Korobkin G. S. Tumyan A. A. Semenova E. G. Kirillova E. M. Volodicheva V. I. Bakhtina T. I. Olkhovik N. R. Solovkova M. V. Demchenkova O. E. Ochirova O. L. Panteleeva V. S. Abramova |
| author_sort | M. V. Solovev |
| collection | DOAJ |
| description | Background. Data from real-life clinical practice studies provide additional information on the efficacy of new antitumor therapy regimens, including in patients who meet exclusion criteria for clinical trials.Aim. To evaluate the Isaomex triplet efficacy in multiple myeloma patients in real clinical practice.Materials and methods. From 2021 to 2024, the retrospective study included 83 double refractory multiple myeloma patients from 26 centers aged 38 to 85 years (median 63), who received the Isaomex triplet. Glomerular filtration rate ˂ 60 mL/min was detected at the time of isatuximabbased triplet initiation in 18 % patients, 2 of whom were on program hemodialysis. The median of previous therapy lines was 2 (1–6). The median time from diagnosis to initiation of isatuximabbased triplet therapy was 47 months (5–203). Survival curves were constructed using the Kaplan–Meier method. Statistical analysis was performed using Statistica 10 program.Results. Isaomex triplet therapy resulted in overall and renal responses in 76 % and 61 % of cases, respectively. The median progression free survival was 13.5 months. In the group of patients who did not receive daratumumab at previous stages, the median progression free survival was significantly higher and was 28 months vs 8 months (p ˂ 0.05). Threeyear overall survival was 81 %. Discontinuation of isatuximab due to the development of adverse event was recorded in 2 cases (2 %). In the group of patients with bone plasmacytomas (n = 46), Isaomex therapy resulted in an overall response rate of 67 %; 12‑month progression free survival was 48 %, and 1‑year overall survival was 76 %.Conclusion. The results of the Isaomex triplet use in real clinical practice for the treatment of relapsed multiple myeloma showed data comparable to the ICARIA registration study on the frequency of achieving a response, duration of progression free survival and overall survival. The triplet efficiency was shown in comorbid patients, with advanced stages and those undergoing renal replacement therapy. |
| format | Article |
| id | doaj-art-ba12ca2068db433ba70931b4e0026398 |
| institution | DOAJ |
| issn | 1818-8346 2413-4023 |
| language | Russian |
| publishDate | 2024-12-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Онкогематология |
| spelling | doaj-art-ba12ca2068db433ba70931b4e00263982025-08-20T03:01:06ZrusABV-pressОнкогематология1818-83462413-40232024-12-0119411512310.17650/1818-8346-2024-19-4-115-123794Efficacy of IsaPomDex triplet therapy in double refractory multiple myeloma patients in real clinical practice in RussiaM. V. Solovev0M. V. Solovevа1L. P. Mendeleeva2T. I. Pospelova3N. V. Skvortsova4S. V. Voloshin5A. D. Garifullin6A. S. Chuprakova7T. A. Mitina8I. S. Usankin9I. V. Vasileva10N. V. Medvedeva11V. V. Ryabchikova12M. Ya. Kiseleva13G. A. Dudina14Yu. S. Gammershmidt15O. S. Kuznetsova16Yu. V. Dolgushina17G. B. Kuchma18T. N. Tsyganok19E. N. Misyurina20E. I. Zhelnova21A. V. Kopylova22M. N. Zakharova23A. V. Korobkin24G. S. Tumyan25A. A. Semenova26E. G. Kirillova27E. M. Volodicheva28V. I. Bakhtina29T. I. Olkhovik30N. R. Solovkova31M. V. Demchenkova32O. E. Ochirova33O. L. Panteleeva34V. S. Abramova35National Medical Research Center for Hematology, Ministry of Health of RussiaNational Medical Research Center for Hematology, Ministry of Health of RussiaNational Medical Research Center for Hematology, Ministry of Health of RussiaNovosibirsk State Medical University, Ministry of Health of RussiaNovosibirsk State Medical University, Ministry of Health of RussiaLeningrad Regional Clinical HospitalRussian Research Institute of Hematology and Transfusiology, Federal Medical and Biological AgencyCentral City Clinical HospitalM.F. Vladimirskiy Moscow Regional Research Clinical InstituteCentral City Hospital No. 7Central City Hospital No. 7City Clinical Hospital No. 31City Clinical Hospital No. 31N.A. Semashko Republican Clinical HospitalA.S. Loginov Moscow Clinical Scientific Center, Moscow Healthcare DepartmentTomsk Regional Clinical HospitalA.A. Lutsik Novokuznetsk City Clinical Hospital No. 29A.A. Lutsik Novokuznetsk City Clinical Hospital No. 29V.I. Voynov Orenburg Regional Clinical HospitalSakhalin Regional Clinical HospitalMoscow City Clinical Hospital No. 52Moscow City Clinical Hospital No. 52Lipetsk Regional Oncological DispensaryChelyabinsk City Clinical Hospital No. 1Chelyabinsk Regional Clinical HospitalN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaRegional Clinical HospitalTula Regional Clinical HospitalRegional Clinical HospitalKrasnoyarsk Interdistrict Clinical Hospital No. 7Irkutsk Regional Clinical HospitalIrkutsk Regional Oncology DispensaryN.A. Semashko Republican Clinical Hospital, Ministry of Health of the Republic of BuryatiaRegional Clinical HospitalRegional Clinical HospitalBackground. Data from real-life clinical practice studies provide additional information on the efficacy of new antitumor therapy regimens, including in patients who meet exclusion criteria for clinical trials.Aim. To evaluate the Isaomex triplet efficacy in multiple myeloma patients in real clinical practice.Materials and methods. From 2021 to 2024, the retrospective study included 83 double refractory multiple myeloma patients from 26 centers aged 38 to 85 years (median 63), who received the Isaomex triplet. Glomerular filtration rate ˂ 60 mL/min was detected at the time of isatuximabbased triplet initiation in 18 % patients, 2 of whom were on program hemodialysis. The median of previous therapy lines was 2 (1–6). The median time from diagnosis to initiation of isatuximabbased triplet therapy was 47 months (5–203). Survival curves were constructed using the Kaplan–Meier method. Statistical analysis was performed using Statistica 10 program.Results. Isaomex triplet therapy resulted in overall and renal responses in 76 % and 61 % of cases, respectively. The median progression free survival was 13.5 months. In the group of patients who did not receive daratumumab at previous stages, the median progression free survival was significantly higher and was 28 months vs 8 months (p ˂ 0.05). Threeyear overall survival was 81 %. Discontinuation of isatuximab due to the development of adverse event was recorded in 2 cases (2 %). In the group of patients with bone plasmacytomas (n = 46), Isaomex therapy resulted in an overall response rate of 67 %; 12‑month progression free survival was 48 %, and 1‑year overall survival was 76 %.Conclusion. The results of the Isaomex triplet use in real clinical practice for the treatment of relapsed multiple myeloma showed data comparable to the ICARIA registration study on the frequency of achieving a response, duration of progression free survival and overall survival. The triplet efficiency was shown in comorbid patients, with advanced stages and those undergoing renal replacement therapy.https://oncohematology.abvpress.ru/ongm/article/view/979relapsed or refractory multiple myelomamonoclonal antibody isatuximabisaomex triplet |
| spellingShingle | M. V. Solovev M. V. Solovevа L. P. Mendeleeva T. I. Pospelova N. V. Skvortsova S. V. Voloshin A. D. Garifullin A. S. Chuprakova T. A. Mitina I. S. Usankin I. V. Vasileva N. V. Medvedeva V. V. Ryabchikova M. Ya. Kiseleva G. A. Dudina Yu. S. Gammershmidt O. S. Kuznetsova Yu. V. Dolgushina G. B. Kuchma T. N. Tsyganok E. N. Misyurina E. I. Zhelnova A. V. Kopylova M. N. Zakharova A. V. Korobkin G. S. Tumyan A. A. Semenova E. G. Kirillova E. M. Volodicheva V. I. Bakhtina T. I. Olkhovik N. R. Solovkova M. V. Demchenkova O. E. Ochirova O. L. Panteleeva V. S. Abramova Efficacy of IsaPomDex triplet therapy in double refractory multiple myeloma patients in real clinical practice in Russia Онкогематология relapsed or refractory multiple myeloma monoclonal antibody isatuximab isaomex triplet |
| title | Efficacy of IsaPomDex triplet therapy in double refractory multiple myeloma patients in real clinical practice in Russia |
| title_full | Efficacy of IsaPomDex triplet therapy in double refractory multiple myeloma patients in real clinical practice in Russia |
| title_fullStr | Efficacy of IsaPomDex triplet therapy in double refractory multiple myeloma patients in real clinical practice in Russia |
| title_full_unstemmed | Efficacy of IsaPomDex triplet therapy in double refractory multiple myeloma patients in real clinical practice in Russia |
| title_short | Efficacy of IsaPomDex triplet therapy in double refractory multiple myeloma patients in real clinical practice in Russia |
| title_sort | efficacy of isapomdex triplet therapy in double refractory multiple myeloma patients in real clinical practice in russia |
| topic | relapsed or refractory multiple myeloma monoclonal antibody isatuximab isaomex triplet |
| url | https://oncohematology.abvpress.ru/ongm/article/view/979 |
| work_keys_str_mv | AT mvsolovev efficacyofisapomdextriplettherapyindoublerefractorymultiplemyelomapatientsinrealclinicalpracticeinrussia AT mvsoloveva efficacyofisapomdextriplettherapyindoublerefractorymultiplemyelomapatientsinrealclinicalpracticeinrussia AT lpmendeleeva efficacyofisapomdextriplettherapyindoublerefractorymultiplemyelomapatientsinrealclinicalpracticeinrussia AT tipospelova efficacyofisapomdextriplettherapyindoublerefractorymultiplemyelomapatientsinrealclinicalpracticeinrussia AT nvskvortsova efficacyofisapomdextriplettherapyindoublerefractorymultiplemyelomapatientsinrealclinicalpracticeinrussia AT svvoloshin efficacyofisapomdextriplettherapyindoublerefractorymultiplemyelomapatientsinrealclinicalpracticeinrussia AT adgarifullin efficacyofisapomdextriplettherapyindoublerefractorymultiplemyelomapatientsinrealclinicalpracticeinrussia AT aschuprakova efficacyofisapomdextriplettherapyindoublerefractorymultiplemyelomapatientsinrealclinicalpracticeinrussia AT tamitina efficacyofisapomdextriplettherapyindoublerefractorymultiplemyelomapatientsinrealclinicalpracticeinrussia AT isusankin efficacyofisapomdextriplettherapyindoublerefractorymultiplemyelomapatientsinrealclinicalpracticeinrussia AT ivvasileva efficacyofisapomdextriplettherapyindoublerefractorymultiplemyelomapatientsinrealclinicalpracticeinrussia AT nvmedvedeva efficacyofisapomdextriplettherapyindoublerefractorymultiplemyelomapatientsinrealclinicalpracticeinrussia AT vvryabchikova efficacyofisapomdextriplettherapyindoublerefractorymultiplemyelomapatientsinrealclinicalpracticeinrussia AT myakiseleva efficacyofisapomdextriplettherapyindoublerefractorymultiplemyelomapatientsinrealclinicalpracticeinrussia AT gadudina efficacyofisapomdextriplettherapyindoublerefractorymultiplemyelomapatientsinrealclinicalpracticeinrussia AT yusgammershmidt efficacyofisapomdextriplettherapyindoublerefractorymultiplemyelomapatientsinrealclinicalpracticeinrussia AT oskuznetsova efficacyofisapomdextriplettherapyindoublerefractorymultiplemyelomapatientsinrealclinicalpracticeinrussia AT yuvdolgushina efficacyofisapomdextriplettherapyindoublerefractorymultiplemyelomapatientsinrealclinicalpracticeinrussia AT gbkuchma efficacyofisapomdextriplettherapyindoublerefractorymultiplemyelomapatientsinrealclinicalpracticeinrussia AT tntsyganok efficacyofisapomdextriplettherapyindoublerefractorymultiplemyelomapatientsinrealclinicalpracticeinrussia AT enmisyurina efficacyofisapomdextriplettherapyindoublerefractorymultiplemyelomapatientsinrealclinicalpracticeinrussia AT eizhelnova efficacyofisapomdextriplettherapyindoublerefractorymultiplemyelomapatientsinrealclinicalpracticeinrussia AT avkopylova efficacyofisapomdextriplettherapyindoublerefractorymultiplemyelomapatientsinrealclinicalpracticeinrussia AT mnzakharova efficacyofisapomdextriplettherapyindoublerefractorymultiplemyelomapatientsinrealclinicalpracticeinrussia AT avkorobkin efficacyofisapomdextriplettherapyindoublerefractorymultiplemyelomapatientsinrealclinicalpracticeinrussia AT gstumyan efficacyofisapomdextriplettherapyindoublerefractorymultiplemyelomapatientsinrealclinicalpracticeinrussia AT aasemenova efficacyofisapomdextriplettherapyindoublerefractorymultiplemyelomapatientsinrealclinicalpracticeinrussia AT egkirillova efficacyofisapomdextriplettherapyindoublerefractorymultiplemyelomapatientsinrealclinicalpracticeinrussia AT emvolodicheva efficacyofisapomdextriplettherapyindoublerefractorymultiplemyelomapatientsinrealclinicalpracticeinrussia AT vibakhtina efficacyofisapomdextriplettherapyindoublerefractorymultiplemyelomapatientsinrealclinicalpracticeinrussia AT tiolkhovik efficacyofisapomdextriplettherapyindoublerefractorymultiplemyelomapatientsinrealclinicalpracticeinrussia AT nrsolovkova efficacyofisapomdextriplettherapyindoublerefractorymultiplemyelomapatientsinrealclinicalpracticeinrussia AT mvdemchenkova efficacyofisapomdextriplettherapyindoublerefractorymultiplemyelomapatientsinrealclinicalpracticeinrussia AT oeochirova efficacyofisapomdextriplettherapyindoublerefractorymultiplemyelomapatientsinrealclinicalpracticeinrussia AT olpanteleeva efficacyofisapomdextriplettherapyindoublerefractorymultiplemyelomapatientsinrealclinicalpracticeinrussia AT vsabramova efficacyofisapomdextriplettherapyindoublerefractorymultiplemyelomapatientsinrealclinicalpracticeinrussia |